Heterocyclic compounds as adenosine antagonists
US11306071B2 · kind B2 · utility
0Cited by
24References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 17, 2020 |
| Grant date | Apr 19, 2022 |
| Priority date | — |
| Expiry date | Feb 10, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
5,6-disubstituted 2-aminopyrazine compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.